RxDoctor Payments Data

Rolf Ehlers, MD

Internal Medicine · San Diego, CANPI 1205939832

Payments from drug & device makers

$8,015in general payments, 2019–2025

Across 404 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$977
  • Lilly USA, LLC$917
  • Novo Nordisk$768
  • Pfizer$733
  • AstraZeneca$560
  • GSK$469
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,93499%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,015 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$215,550
Medicare patients
559
Services billed
6,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$134,090
OzempicSemaglutide44$77,886
RybelsusSemaglutide50$66,682
XareltoRivaroxaban64$61,878
XeljanzTofacitinib Citrate11$54,750
JanuviaSitagliptin Phosphate37$52,359
FarxigaDapagliflozin Propanediol35$45,241
MounjaroTirzepatide22$39,752
TrulicityDulaglutide24$30,979
JardianceEmpagliflozin26$30,277
ProliaDenosumab11$19,277
EntrestoSacubitril/Valsartan14$10,961
BrilintaTicagrelor14$9,675
Rosuvastatin Calcium260$7,699
Breo ElliptaFluticasone/Vilanterol11$7,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$733$188,840136 claims
Novo NordiskOzempic, Rybelsus$768$144,56894 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$917$75,31567 claims
Johnson & JohnsonXarelto$166$61,87864 claims
AstraZenecaFarxiga, Brilinta$560$54,91649 claims
MerckJanuvia$106$52,35937 claims
Boehringer IngelheimJardiance, Spiriva Respimat$154$37,08938 claims
AmgenProlia$193$19,27711 claims
NovartisEntresto$182$10,96114 claims
GSKBreo Ellipta$469$7,18911 claims
AbbVieSynthroid$977$3,61477 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →